Bio-Techne Stock Upgraded As Analyst Flags Attractive Entry Point

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, creating an attractive entry point.

Bio-Techne reported fourth-quarter adjusted earnings of 53 cents. It beat the consensus of 50 cents. Sales reached $316.96 million, beating the consensus of $316 million.

“Bio-Techne CEO Kim Kelderman praised the quarter for being “in line” with expectations, despite market uncertainty.

The company also agreed to sell its Exosome Diagnostics Inc. business and related assets to Mdxhealth.

Kelderman said, “This strategic decision will immediately strengthen our profitability and allow us to increase our focus on high-growth areas, particularly tools for research and precision ...